$25 – $2,500

Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium

Actions and Detail Panel

$25 – $2,500

Event Information

Share this event

Date and time

Location

Location

Loews Vanderbilt Hotel

2100 West End Avenue

Nashville, TN 37203

View Map

Event description
Emerging applications of novel therapies in hematologic disorders and solid tumors

About this event

**Due to group gathering restrictions because of COVID-19, the symposium has been rescheduled and will now be a hybrid live AND virtual option!**

Vanderbilt-Ingram Cancer Center would like you to join us at our inaugural Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium, with focus on current advances in stem cell transplantation and cancer cell therapy, emerging applications of these novel therapies in hematologic disorders and solid tumors.

This activity has been approved for AMA PRA Category 1 Credit™.

Speakers:

Frederick Locke, MD, Program Co-Leader, Immunology. Specialty: Blood and Marrow Transplant and Cellular Immunotherapy

Program: Blood and Marrow Transplant and Cellular Immunotherapy

Cancer Focus: Hodgkin Lymphoma , Leukemia , Multiple Myeloma-Plasma Cell Tumor , Non-Hodgkin Lymphoma

Dr. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr. Locke graduated with a B.S. in Physiology from Michigan State University, and with an M.D. from Wayne State University. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. Dr. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago. Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.

Richard John Jones, M.D. Director Bone Marrow Transplantation Program

Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty.

Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program.

HOTEL INFO:

We have a block of rooms at Loews Vanderbilt Hotel, and you can use this link to book your stay. You may also book by calling (800) 336-3335 - please refer to the accurate dates and the Stem Cell Transplant Symposium block. The cutoff date for this block of rooms is March 4th!

Share with friends

Date and time

Location

Loews Vanderbilt Hotel

2100 West End Avenue

Nashville, TN 37203

View Map

{ _('Organizer Image')}

Organizer Vanderbilt-Ingram Cancer Center

Organizer of Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium

Save This Event

Event Saved